Lateral Epicondylalgia (Tennis Elbow) Clinical Trial
| NCT number | NCT00631501 |
| Other study ID # | BE-2-47 |
| Secondary ID | |
| Status | Recruiting |
| Phase | N/A |
| First received | February 27, 2008 |
| Last updated | February 27, 2008 |
Matrix metalloproteinases are involved in the pathogenesis of tendinopathy. Doxycycline, a
widely available pharmaceutical agent mostly used for its antibiotic properties, also
functions as an inhibitor of MMPs.
This study aims to investigate the effect of doxycycline treatment on lateral epicondylalgia
(tennis elbow). During three weeks, patients receive doxycycline tablets 100 mg twice daily,
or placebo. Main outcome variable is pain (VAS) at three weeks.
Serum and/or plasma levels of matrix metalloproteinases and tissue inhibitors of
metalloproteinases are measured.
| Status | Recruiting |
| Enrollment | 34 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: - Age 18-65 - Pain at the lateral side of the elbow =8 weeks - Local tenderness on palpation of the lateral epicondyle - Pain on resisted extension of the wrist Exclusion Criteria: - Rheumatic disorder - History of fibromyalgia or generalised pain - Elbow surgery (on the painful side) - Active infection - Glucocorticoid treatment during the duration of symtoms of epicondylalgia - NSAID use within 1 w before presentation and during the study - Pregnancy - Taking drug that might interact with doxycycline |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| Lithuania | Dept of Orthopaedics, Kaunas Medical University | Kaunas |
| Lead Sponsor | Collaborator |
|---|---|
| Kaunas University of Medicine | University Hospital, Linkoeping |
Lithuania,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Pain (VAS) | No |